Atrah H I, Crawford R J, Dow B C, Mitchell R
J Clin Pathol. 1985 Oct;38(10):1192-3. doi: 10.1136/jcp.38.10.1192.
In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin products can apparently transmit non-A, non-B hepatitis.
在一项针对16例患者的前瞻性临床和生化研究中，这些患者接受了高剂量经pH 4条件下轻度胃蛋白酶处理而改良用于静脉注射的免疫球蛋白产品治疗，未发现肝炎迹象。这与最近有关静脉注射免疫球蛋白产品显然可传播非甲非乙型肝炎的报道形成对比。
